アブストラクト
Japanese
| Title | カルボプラチンベースの化学療法を受けた肺がん患者におけるパロノセトロン + デキサメタゾン (1日投与) + ホスアプレピタント + オランザピン2.5mgの有効性と安全性の評価 |
|---|---|
| Subtitle | ノート |
| Authors | 三瓶祐貴, 奥田泰考, 品田誠, 齋藤賢宏, 小林直人, 山下尊子, 中田雅人, 荒井大地, 大平実佳, 田村依珠美, 今井靖 |
| Authors (kana) | |
| Organization | 自治医科大学附属病院薬剤部 |
| Journal | 医療薬学 |
| Volume | 50 |
| Number | 10 |
| Page | 531-538 |
| Year/Month | 2024 / 10 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」 化学療法誘発性悪心・嘔吐(chemotherapy-induced nausea and vomiting: CINV)の予防は, 化学療法の継続に直接影響し, 患者のquality of life (QOL)に影響を及ぼす臨床上の大きな問題である. 本邦の制吐薬適正使用ガイドラインではarea under the curve (AUC)4以上, 国際がん支持療法学会(Multinational Association of Supportive Care in Cancer: MASCC)の最新のガイドラインではAUC 5以上のカルボプラチンを含む化学療法を受ける患者にはニューロキニン1(NK1)受容体拮抗薬, デキサメタゾン(DEX), セロトニン5-HT3受容体拮抗薬を含む予防的制吐療法が推奨されている. デキサメタゾンはCINVに対する効果的な制吐薬として長年使用されてきたが, 反復投与に伴う高血糖や骨粗鬆症などの副作用が懸念される. 近年, デキサメタゾンを化学療法1日目から4日目まで投与する従来の方法から化学療法2日目以降の投与を省略するステロイドスペアリングの有効性が, 幾つかの臨床試験にて報告されている. |
| Practice | 薬学 |
| Keywords | chemotherapy-induced nausea and vomiting, carboplatin, olanzapine, steroid sparing |
English
| Title | Evaluation of the Efficacy and Safety of Palonosetron + Dexamethasone (1-day) + Fosaprepitant + Olanzapine (2.5 mg) in Patients with Lung Cancer Undergoing Carboplatin-based Chemotherapy |
|---|---|
| Subtitle | |
| Authors | Yuki Mikame, Yasunari Okuda, Makoto Shinada, Takahiro Saito, Naoto Kobayashi, Takako Yamashita, Masato Nakata, Daichi Arai, Mika Ohira, Izumi Tamura, Yasushi Imai |
| Authors (kana) | |
| Organization | Department of Pharmacy, Jichi Medical University Hospital |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 50 |
| Number | 10 |
| Page | 531-538 |
| Year/Month | 2024 / 10 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Chemotherapy-induced nausea and vomiting (CINV) remains an unresolved medical condition, and suitable combinations for a 1-day dexamethasone antiemetic regimen have not been adequately investigated for carboplatin-based chemotherapy. Herein, we evaluated the efficacy of olanzapine (2.5 mg) combined with an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and a 1-day dexamethasone antiemetic regimen in patients with lung cancer who received carboplatin-based chemotherapy. The efficacy and safety of olanzapine against CINV were compared between two propensity score-matched groups of 22 patients each. The primary endpoint, complete response rate in the delayed phase, and secondary endpoints, including the overall incidence of nausea, incidence of grade >-2 nausea, and time to treatment failure, were considerably improved in the olanzapine group. The results indicate that the addition of olanzapine (2.5 mg) to a triple antiemetic regimen of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and 1-day dexamethasone may be a useful option for patients undergoing carboplatin-based chemotherapy. |
| Practice | Pharmaceutical sciences |
| Keywords | chemotherapy-induced nausea and vomiting, carboplatin, olanzapine, steroid |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
